"Johnson & Johnson discontinues Phase III study of treatment for bladder cancer" was originally created and published by ...

J&J acquired rights to the silicone-based drug delivery service used in TAR-200, which allows for the continuous release of ...

The sun has set on Johnson & Johnson’s SunRISe-2 study. J&J called a halt to the phase 3 bladder cancer trial after an ...

A Johnson & Johnson banner is displayed on the front of the New York Stock Exchange (NYSE) in New York City, in New York City, U.S. Johnson & Johnson said on Monday it has discontinued a late-stage ...

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) and keeping the price ...

The SunRISe-2 trial evaluating TAR-200 combined with cetrelimab vs chemoradiation in muscle-invasive bladder cancer has been ...

Prostate cancer treatment can be lifesaving, but it can also cause many side effects. Learn how you can manage them.

Analysis by Macmillan estimates that around 60,000 women diagnosed with cancer under the age of 50 are struggling with ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on CG Oncology, Inc. (CGON – Research Report). The ...

The FDA has granted VLS-1488 fast track designation in patients with platinum-resistant high-grade serous ovarian cancer.

The University is part of a nationwide team launching a new platform to understand immunotherapy response and side effects in ...

Can you treat prostate cancer? Here is how robotic surgeries can help to stop these malignant cancer cell growths inside the ...